Peter Zhou co-founded and leads both a venture firm (Triatomic) and a fundamental long/short hybrid hedge fund (Hongkou Capital), giving him an uncommon combination of public-markets hedge fund experience and early-stage venture investing in the same platform. He frequently leads or joins boards in highly technical, deep-tech companies like Elegen in next-generation DNA manufacturing and iPronics in reconfigurable photonics for AI data centers, reinforcing a reputation for engaging with complex, science-heavy businesses rather than just software or consumer deals.
About their Fund
Triatomic Capital is a venture fund that writes checks from $100k to $25M across early to growth stages, focusing on "century-defining themes" like next-gen compute, automated economy, new materials, engineered biology, and new energy—positioning itself as a cross-vertical applied AI specialist that looks for AI as an enabling layer in physical-world and life-science problems rather than software plays. The fund combines deep health-tech and healthcare systems experience with frontier-tech investing expertise, creating an unusual bridge between regulated health systems and cutting-edge AI/deep tech startups while investing globally across the US and Asia-Pacific markets in infrastructure-focused companies rather than consumer AI applications.
























.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)


















































































.jpeg)

